Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pharmacist-Led lessons may cut infection risk in chemo patients

NCT ID NCT07690956

Knowledge-focused Sponsor: Jordan University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial tests whether a pharmacist-led educational program helps cancer patients on high-risk chemotherapy better understand and follow neutropenic precautions—steps to prevent serious infections when white blood cell counts are low. About 300 adults with various cancers will either receive standard care or additional education including written materials, a counseling session, and a video. Researchers will measure changes in knowledge, adherence to precautions, and infection rates over 2-6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pharmacist-Led Neutropenic Education Package (P-NEP)
What this could lead to
If effective, this educational approach could reduce infection rates and improve safety for cancer patients undergoing chemotherapy.
What could go wrong
This is a single-center study with 300 participants, so results may not apply broadly. The intervention relies on self-reported adherence, which can be biased.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

Jul 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: -You may be able to join this study if all of the following apply to you: * You are 18 years or older. * You have been diagnosed with any type of cancer (such as breast, colon, lymphoma, etc.). * You are currently receiving chemotherapy that has a high risk of lowering your white blood cell count. * You are receiving treatment in outpatient (infusion centers) or inpatient settings (oncology wards). Exclusion Criteria: * You cannot join this study if any of the following apply to you: * You currently have an active infection (such as fever or diagnosed illness). * You are unable to speak Arabic or English, and do not have a caregiver who can help with the study. * You have a major psychiatric condition that makes it difficult to understand or participate in the educational activities.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Febrile Neutropenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Febrile neutropenia

Contacts and locations

Locations

  • AlBashir Hospital

    Amman, 11151, Jordan

  • King Abdullah University Hospital (KAUH)

    Irbid, 22110, Jordan

More trials for these conditions

Other studies related to the condition(s) this trial covers.